Search research articles
Contact Us
Filters
Showing results (461-470 of 590) with videos related to
Page
of 59
Sort By:
Future Oncology (London, England)
|
May 11, 2026
Phase III randomized studies of mevrometostat and enzalutamide in metastatic prostate cancer (MEVPRO-1 and MEVPRO-2): trial protocols
Neal D Shore, Karim Fizazi, Michael Thomas Schweizer, et al.
The Prostate
|
March 5, 2020
Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines
Neal D Shore, Emmanuel S Antonarakis, Michael S Cookson, et al.
The Journal of Urology
|
December 28, 2020
Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses
Andrew J Armstrong, Neal D Shore, Russell Z Szmulewitz, et al.
Urologic Oncology
|
March 23, 2017
The potential role of follicle-stimulating hormone in the cardiovascular, metabolic, skeletal, and cognitive effects associated with androgen deprivation therapy
E David Crawford, Andrew V Schally, Jehonathan H Pinthus, et al.
Eclinicalmedicine
|
May 30, 2023
Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancer
Celestia S Higano, Daniel J George, Neal D Shore, et al.
The Journal of Urology
|
March 11, 2021
Reply by Authors
Andrew J Armstrong, Neal D Shore, Russell Z Szmulewitz, et al.
The New England Journal of Medicine
|
September 8, 2010
Sipuleucel-T immunotherapy for castration-resistant prostate cancer
Philip W Kantoff, Celestia S Higano, Neal D Shore, et al.
European Urology
|
April 11, 2020
The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial
David P Dearnaley, Daniel R Saltzstein, John E Sylvester, et al.
European Urology
|
February 3, 2026
ARCHES 5-year Survival with Enzalutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients
Andrew J Armstrong, Daniel P Petrylak, Neal D Shore, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 19, 2017
Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone
Dana E Rathkopf, Emmanuel S Antonarakis, Neal D Shore, et al.
Page
of 59
Search research articles
Search
Showing results (461-470 of 590) with videos related to
Sort By:
Page
of 59
Future Oncology (London, England)
|
May 11, 2026
Phase III randomized studies of mevrometostat and enzalutamide in metastatic prostate cancer (MEVPRO-1 and MEVPRO-2): trial protocols
Neal D Shore, Karim Fizazi, Michael Thomas Schweizer, et al.
The Prostate
|
March 5, 2020
Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines
Neal D Shore, Emmanuel S Antonarakis, Michael S Cookson, et al.
The Journal of Urology
|
December 28, 2020
Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses
Andrew J Armstrong, Neal D Shore, Russell Z Szmulewitz, et al.
Urologic Oncology
|
March 23, 2017
The potential role of follicle-stimulating hormone in the cardiovascular, metabolic, skeletal, and cognitive effects associated with androgen deprivation therapy
E David Crawford, Andrew V Schally, Jehonathan H Pinthus, et al.
Eclinicalmedicine
|
May 30, 2023
Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancer
Celestia S Higano, Daniel J George, Neal D Shore, et al.
The Journal of Urology
|
March 11, 2021
Reply by Authors
Andrew J Armstrong, Neal D Shore, Russell Z Szmulewitz, et al.
The New England Journal of Medicine
|
September 8, 2010
Sipuleucel-T immunotherapy for castration-resistant prostate cancer
Philip W Kantoff, Celestia S Higano, Neal D Shore, et al.
European Urology
|
April 11, 2020
The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial
David P Dearnaley, Daniel R Saltzstein, John E Sylvester, et al.
European Urology
|
February 3, 2026
ARCHES 5-year Survival with Enzalutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients
Andrew J Armstrong, Daniel P Petrylak, Neal D Shore, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 19, 2017
Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone
Dana E Rathkopf, Emmanuel S Antonarakis, Neal D Shore, et al.
Page
of 59